fact_key,concept,context_ref,value,unit_ref,decimals,numeric_value,period_type,period_start,period_end,entity_identifier,entity_scheme,period_key,label,original_label,statement_type,statement_role,period_instant,dim_us-gaap_StatementEquityComponentsAxis,dim_us-gaap_ConcentrationRiskByTypeAxis,dim_srt_ProductOrServiceAxis,dim_us-gaap_TypeOfArrangementAxis,dim_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis,dim_us-gaap_FairValueByMeasurementFrequencyAxis,dim_us-gaap_FinancialInstrumentAxis,dim_us-gaap_FairValueByFairValueHierarchyLevelAxis,dim_srt_RangeAxis,dim_us-gaap_FairValueByAssetClassAxis,dim_srt_CounterpartyNameAxis,dim_us-gaap_IncomeStatementLocationAxis,dim_us-gaap_OtherCommitmentsAxis,dim_us-gaap_SubsidiarySaleOfStockAxis,ticker,filing_date,quarter,year,company_name
us-gaap_EarningsPerShareDiluted_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:EarningsPerShareDiluted,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-0.04,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.04,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:EarningsPerShareDiluted,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-0.05,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.05,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:EarningsPerShareDiluted,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-0.14,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.14,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:EarningsPerShareDiluted,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-0.13,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.13,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:CommonStockSharesOutstanding,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,982719936,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,982719936.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityFilerCategory_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityFilerCategory,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,Large Accelerated Filer,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Filer Category,Entity Filer Category,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityCentralIndexKey_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityCentralIndexKey,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,0001621227,None,None,1621227.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Central Index Key,Entity Central Index Key,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_CurrentFiscalYearEndDate_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:CurrentFiscalYearEndDate,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,--12-31,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Current Fiscal Year End Date,Current Fiscal Year End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_DocumentFiscalYearFocus_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:DocumentFiscalYearFocus,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,2022,None,None,2022.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Document Fiscal Year Focus,Document Fiscal Year Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_DocumentFiscalPeriodFocus_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:DocumentFiscalPeriodFocus,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,Q3,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Document Fiscal Period Focus,Document Fiscal Period Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_AmendmentFlag_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:AmendmentFlag,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,false,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Amendment Flag,Amendment Flag,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityTaxIdentificationNumber_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityTaxIdentificationNumber,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,00-0000000,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Tax Identification Number,Entity Tax Identification Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,937547934,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,937547934.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Numerator for diluted loss per share,Numerator for diluted loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Numerator for diluted loss per share,Numerator for diluted loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136206000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136206000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Numerator for diluted loss per share,Numerator for diluted loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119232000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119232000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Numerator for diluted loss per share,Numerator for diluted loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_0,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,980791114,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,980791114.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_1,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,980791114,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,980791114.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_0,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,936600648,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,936600648.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_1,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,936600648,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,936600648.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_0,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,961354122,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,961354122.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_1,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,961354122,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,961354122.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_0,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,933992708,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,933992708.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_1,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,933992708,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,933992708.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Denominator for diluted loss per share - Weighted average shares outstanding,Denominator for diluted loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_DocumentType_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:DocumentType,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,10-Q,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Document Type,Document Type,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_DocumentQuarterlyReport_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:DocumentQuarterlyReport,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,true,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Document Quarterly Report,Document Quarterly Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_DocumentPeriodEndDate_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:DocumentPeriodEndDate,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,2022-09-30,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Document Period End Date,Document Period End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_DocumentTransitionReport_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:DocumentTransitionReport,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,false,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Document Transition Report,Document Transition Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityFileNumber_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityFileNumber,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,001-37368,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity File Number,Entity File Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityRegistrantName_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityRegistrantName,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,ADAPTIMMUNE THERAPEUTICS PLC,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Registrant Name,Entity Registrant Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityIncorporationStateCountryCode_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityIncorporationStateCountryCode,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,X0,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Entity Incorporation, State or Country Code","Entity Incorporation, State or Country Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityAddressAddressLine1_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityAddressAddressLine1,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"60 Jubilee Avenue, Milton Park",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Entity Address, Address Line One","Entity Address, Address Line One",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityAddressCityOrTown_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityAddressCityOrTown,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"Abingdon, Oxfordshire",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Entity Address, City or Town","Entity Address, City or Town",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityAddressPostalZipCode_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityAddressPostalZipCode,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,OX14 4RX,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Entity Address, Postal Zip Code","Entity Address, Postal Zip Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityAddressCountry_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityAddressCountry,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,GB,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Entity Address, Country","Entity Address, Country",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_CityAreaCode_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:CityAreaCode,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,44,None,None,44.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,City Area Code,City Area Code,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_LocalPhoneNumber_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:LocalPhoneNumber,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,1235 430000,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Local Phone Number,Local Phone Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_Security12bTitle_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:Security12bTitle,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Title of 12(b) Security,Title of 12(b) Security,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_TradingSymbol_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:TradingSymbol,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,ADAP,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Trading Symbol,Trading Symbol,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_SecurityExchangeName_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:SecurityExchangeName,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,NASDAQ,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Security Exchange Name,Security Exchange Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityCurrentReportingStatus_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityCurrentReportingStatus,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,Yes,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Current Reporting Status,Entity Current Reporting Status,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityInteractiveDataCurrent_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityInteractiveDataCurrent,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,Yes,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Interactive Data Current,Entity Interactive Data Current,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntitySmallBusiness_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntitySmallBusiness,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,false,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Small Business,Entity Small Business,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityEmergingGrowthCompany_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityEmergingGrowthCompany,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,false,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Emerging Growth Company,Entity Emerging Growth Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityShellCompany_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,dei:EntityShellCompany,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,false,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Entity Shell Company,Entity Shell Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
dei_EntityCommonStockSharesOutstanding_As_Of_11_7_2022_wLbmmZ-IMU2U2ebZYU2mcg,dei:EntityCommonStockSharesOutstanding,As_Of_11_7_2022_wLbmmZ-IMU2U2ebZYU2mcg,982974108,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,982974108.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-11-07,"Entity Common Stock, Shares Outstanding","Entity Common Stock, Shares Outstanding",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2022-11-07,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,149948000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,149948000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,219632000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,219632000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Allowance for doubtful accounts,Allowance for doubtful accounts,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Allowance for doubtful accounts,Allowance for doubtful accounts,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AccountsReceivableNetCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1774000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1774000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Accounts receivable, net of allowance for doubtful accounts of $0 and $0","Accounts receivable, net of allowance for doubtful accounts of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,752000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,752000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Accounts receivable, net of allowance for doubtful accounts of $0 and $0","Accounts receivable, net of allowance for doubtful accounts of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,62695000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,62695000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,45126000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,45126000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AssetsCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,264139000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,264139000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AssetsCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,415458000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,415458000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,1718000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1718000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,17607000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,17607000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Operating lease right-of-use assets, net of accumulated amortization","Operating lease right-of-use assets, net of accumulated amortization",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,20875000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,20875000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Operating lease right-of-use assets, net of accumulated amortization","Operating lease right-of-use assets, net of accumulated amortization",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,35229000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,35229000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,36253000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,36253000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:PropertyPlantAndEquipmentNet,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,48176000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,48176000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Property, plant and equipment, net of accumulated depreciation of $35,229 and $36,253","Property, plant and equipment, net of accumulated depreciation of $35,229 and $36,253",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:PropertyPlantAndEquipmentNet,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,30494000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,30494000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Property, plant and equipment, net of accumulated depreciation of $35,229 and $36,253","Property, plant and equipment, net of accumulated depreciation of $35,229 and $36,253",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AmortizationOfIntangibleAssets_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:AmortizationOfIntangibleAssets,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,4354000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4354000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Intangible assets, net of accumulated amortization","Intangible assets, net of accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AmortizationOfIntangibleAssets_Duration_1_1_2021_To_12_31_2021_2_n_5Ge2LUaX2tSNNUwjPA,us-gaap:AmortizationOfIntangibleAssets,Duration_1_1_2021_To_12_31_2021_2_n_5Ge2LUaX2tSNNUwjPA,4051000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4051000.0,duration,2021-01-01,2021-12-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-12-31,"Intangible assets, net of accumulated amortization","Intangible assets, net of accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,568000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,568000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Intangible assets, net of accumulated amortization of $4,354 and $4,051","Intangible assets, net of accumulated amortization of $4,354 and $4,051",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,1000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Intangible assets, net of accumulated amortization of $4,354 and $4,051","Intangible assets, net of accumulated amortization of $4,354 and $4,051",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:Assets,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,332202000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,332202000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:Assets,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,469545000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,469545000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AccountsPayableCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,6905000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6905000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AccountsPayableCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,8113000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8113000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,2474000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2474000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,2320000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2320000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,20622000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,20622000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,22199000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,22199000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LiabilitiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,66080000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,66080000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:LiabilitiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,62541000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,62541000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,19926000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,19926000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,23148000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,23148000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityNoncurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:ContractWithCustomerLiabilityNoncurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,132233000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,132233000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityNoncurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:ContractWithCustomerLiabilityNoncurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,177223000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,177223000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OtherLiabilitiesNoncurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,626000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,626000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OtherLiabilitiesNoncurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,673000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,673000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:Liabilities,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,218865000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,218865000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:Liabilities,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,263585000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,263585000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,0.001,Unit_Divide_GBP_shares_iUl3QGUJTE6gFiEYd3EorA,3,0.001,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,0.001,Unit_Divide_GBP_shares_iUl3QGUJTE6gFiEYd3EorA,3,0.001,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:CommonStockSharesAuthorized,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1282773750,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,1282773750.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:CommonStockSharesIssued,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,982719936,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,982719936.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CommonStockSharesAuthorized,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,1240853520,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,1240853520.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CommonStockSharesIssued,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,937547934,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,937547934.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:CommonStockValue,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1394000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1394000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 982,719,936 issued and outstanding (2021: 1,240,853,520 authorized and 937,547,934 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 982,719,936 issued and outstanding (2021: 1,240,853,520 authorized and 937,547,934 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CommonStockValue,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,1337000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 982,719,936 issued and outstanding (2021: 1,240,853,520 authorized and 937,547,934 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 982,719,936 issued and outstanding (2021: 1,240,853,520 authorized and 937,547,934 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AdditionalPaidInCapital,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,985312000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,985312000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AdditionalPaidInCapital,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,959611000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,959611000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,6683000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6683000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,-11142000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-11142000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,-743846000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-743846000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,332202000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,332202000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,469545000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,469545000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:ResearchAndDevelopmentExpense,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,33182000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,33182000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:ResearchAndDevelopmentExpense,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,28211000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,28211000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,104674000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,104674000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,81585000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,81585000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:GeneralAndAdministrativeExpense,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,16815000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,16815000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:GeneralAndAdministrativeExpense,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,15173000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15173000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:GeneralAndAdministrativeExpense,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,48169000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,48169000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:GeneralAndAdministrativeExpense,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,42529000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,42529000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:CostsAndExpenses,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-49997000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-49997000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:CostsAndExpenses,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-43384000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-43384000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:CostsAndExpenses,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-152843000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-152843000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:CostsAndExpenses,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-124114000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-124114000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OperatingIncomeLoss,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-42990000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42990000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Operating loss,Operating loss,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OperatingIncomeLoss,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42181000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42181000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Operating loss,Operating loss,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OperatingIncomeLoss,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136723000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136723000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Operating loss,Operating loss,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OperatingIncomeLoss,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119382000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119382000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Operating loss,Operating loss,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,324000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,324000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,225000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,225000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,1019000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1019000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,916000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,916000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherNonoperatingIncomeExpense,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,1644000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1644000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Other (expense) income, net","Other (expense) income, net",IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherNonoperatingIncomeExpense,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-237000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-237000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Other (expense) income, net","Other (expense) income, net",IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,1001000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1001000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Other (expense) income, net","Other (expense) income, net",IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-184000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-184000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Other (expense) income, net","Other (expense) income, net",IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41022000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41022000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Loss before income tax expense,Loss before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42193000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42193000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Loss before income tax expense,Loss before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-134703000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-134703000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Loss before income tax expense,Loss before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-118650000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-118650000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Loss before income tax expense,Loss before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:IncomeTaxExpenseBenefit,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-399000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-399000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:IncomeTaxExpenseBenefit,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-208000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-208000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-1503000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1503000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-582000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-582000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:EarningsPerShareBasic,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-0.04,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.04,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:EarningsPerShareBasic,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-0.05,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.05,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:EarningsPerShareBasic,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-0.14,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.14,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:EarningsPerShareBasic,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-0.13,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,-0.13,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_0,us-gaap:NetIncomeLoss,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_1,us-gaap:NetIncomeLoss,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_0,us-gaap:NetIncomeLoss,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_1,us-gaap:NetIncomeLoss,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_0,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136206000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136206000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_1,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136206000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136206000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_0,us-gaap:NetIncomeLoss,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119232000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119232000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_1,us-gaap:NetIncomeLoss,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119232000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119232000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,58011000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,58011000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,15564000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15564000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,122496000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,122496000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,8386000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8386000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-50489000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-50489000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-15310000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-15310000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-103404000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-103404000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-8351000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-8351000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,204000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,204000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,33000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,33000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-1267000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1267000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-85000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-85000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:ComprehensiveIncomeNetOfTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-33695000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-33695000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Total comprehensive loss for the period,Total comprehensive loss for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:ComprehensiveIncomeNetOfTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42114000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42114000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Total comprehensive loss for the period,Total comprehensive loss for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-118381000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-118381000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Total comprehensive loss for the period,Total comprehensive loss for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119282000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119282000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Total comprehensive loss for the period,Total comprehensive loss for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QOjZpTaXC0OEETn-YPxaVg,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QOjZpTaXC0OEETn-YPxaVg,937547934,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,937547934.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QOjZpTaXC0OEETn-YPxaVg,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QOjZpTaXC0OEETn-YPxaVg,1337000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_roBahcdcKEi1sCdyU8_uEA,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_roBahcdcKEi1sCdyU8_uEA,959611000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,959611000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xpdyzboj80-1MLt04NowCw,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xpdyzboj80-1MLt04NowCw,-11142000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-11142000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lBukRmL2okO4KvOM0tzcvw,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lBukRmL2okO4KvOM0tzcvw,-743846000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-743846000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA_0,us-gaap:StockholdersEquity,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,205960000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,205960000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA_1,us-gaap:StockholdersEquity,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,205960000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,205960000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7CvT9TC7zkufNkDm2SviFg,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7CvT9TC7zkufNkDm2SviFg,-50265000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,-50265000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,1829000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1829000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,1829000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1829000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kxCVIeSQwEaA4ZPNiTy3Bg,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kxCVIeSQwEaA4ZPNiTy3Bg,3318072,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,3318072.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kxCVIeSQwEaA4ZPNiTy3Bg,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kxCVIeSQwEaA4ZPNiTy3Bg,5000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wv0h9hRS2Uq-TSgRu9bygg,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wv0h9hRS2Uq-TSgRu9bygg,30000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,30000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,35000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,35000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wv0h9hRS2Uq-TSgRu9bygg,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wv0h9hRS2Uq-TSgRu9bygg,5586000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5586000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,5586000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5586000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u1oINTcFskSsJLH-MizeVA,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u1oINTcFskSsJLH-MizeVA,940866006,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,940866006.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u1oINTcFskSsJLH-MizeVA,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u1oINTcFskSsJLH-MizeVA,1342000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1342000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BXpi9o8vckOuKDRUjPSo6Q,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BXpi9o8vckOuKDRUjPSo6Q,965227000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,965227000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rBxVXVUXwU-dJFJSuBY4NA,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rBxVXVUXwU-dJFJSuBY4NA,-9313000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-9313000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1vl2vMW0Tk-0d_aSllyZSA,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1vl2vMW0Tk-0d_aSllyZSA,-794111000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-794111000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_xyOWBWi1VUeKhpWkCv_33A,us-gaap:StockholdersEquity,As_Of_3_31_2022_xyOWBWi1VUeKhpWkCv_33A,163145000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,163145000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Hr2WR6O-LU-v3wBc-4zCPg,us-gaap:NetIncomeLoss,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Hr2WR6O-LU-v3wBc-4zCPg,-44520000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-44520000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:NetIncomeLoss,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,-44520000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-44520000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,8270000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8270000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,8270000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8270000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,759336,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,759336.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,1000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,1000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,35134182,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,35134182.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uNXbtVSA7EeXG2U7sjEEIw,44000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,44000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nJVUX9SacUaQZMn-B26YVw,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nJVUX9SacUaQZMn-B26YVw,9932000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,9932000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,9976000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,9976000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nJVUX9SacUaQZMn-B26YVw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nJVUX9SacUaQZMn-B26YVw,5045000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5045000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,5045000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5045000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFWK-00BoUmJMq-PWQCTqQ,us-gaap:CommonStockSharesOutstanding,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFWK-00BoUmJMq-PWQCTqQ,976759524,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,976759524.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-06-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFWK-00BoUmJMq-PWQCTqQ,us-gaap:StockholdersEquity,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFWK-00BoUmJMq-PWQCTqQ,1387000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1387000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BZAKTfW5hEerZG0_Rf60zw,us-gaap:StockholdersEquity,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BZAKTfW5hEerZG0_Rf60zw,980204000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,980204000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ypeqBfn63k2rbFsWXukkyQ,us-gaap:StockholdersEquity,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ypeqBfn63k2rbFsWXukkyQ,-1043000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1043000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j6M_McoKIEm8T7N9XxyacA,us-gaap:StockholdersEquity,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j6M_McoKIEm8T7N9XxyacA,-838631000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-838631000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2022_TlQNsrP4mEWyv_lNg6nBSw,us-gaap:StockholdersEquity,As_Of_6_30_2022_TlQNsrP4mEWyv_lNg6nBSw,141917000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,141917000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8rnJjfYIZUKEpA_Q1ALH5g,us-gaap:NetIncomeLoss,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8rnJjfYIZUKEpA_Q1ALH5g,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_2,us-gaap:NetIncomeLoss,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,7726000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7726000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,7726000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7726000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,1005558,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,1005558.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,1000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LDSH3SNHnUubgZw4r5ZFqQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LDSH3SNHnUubgZw4r5ZFqQ,5000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,6000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,4954854,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,4954854.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0TexVDlQS0GIBj0QkR9bVg,6000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LDSH3SNHnUubgZw4r5ZFqQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LDSH3SNHnUubgZw4r5ZFqQ,1440000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1440000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,1446000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1446000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LDSH3SNHnUubgZw4r5ZFqQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LDSH3SNHnUubgZw4r5ZFqQ,3663000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3663000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,3663000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3663000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ScFXmHGPzk-zv4kbFYOe9w,us-gaap:CommonStockSharesOutstanding,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ScFXmHGPzk-zv4kbFYOe9w,982719936,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,982719936.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-09-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ScFXmHGPzk-zv4kbFYOe9w,us-gaap:StockholdersEquity,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ScFXmHGPzk-zv4kbFYOe9w,1394000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1394000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_amCLgClCoUqUhRC0fu8upQ,us-gaap:StockholdersEquity,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_amCLgClCoUqUhRC0fu8upQ,985312000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,985312000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IJMI7opmwEaMtYX99ZCnGQ,us-gaap:StockholdersEquity,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IJMI7opmwEaMtYX99ZCnGQ,6683000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6683000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WTljmh2MMUSzjV-dzCVJYQ,us-gaap:StockholdersEquity,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WTljmh2MMUSzjV-dzCVJYQ,-880052000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-880052000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_0,us-gaap:StockholdersEquity,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,113337000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,113337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_1,us-gaap:StockholdersEquity,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,113337000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,113337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G39AiNB66kWN9IQHm7NLPw,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G39AiNB66kWN9IQHm7NLPw,928754958,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,928754958.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2020-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G39AiNB66kWN9IQHm7NLPw,us-gaap:StockholdersEquity,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G39AiNB66kWN9IQHm7NLPw,1325000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1325000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nUctZgqIA06Xeq3YzORhlw,us-gaap:StockholdersEquity,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nUctZgqIA06Xeq3YzORhlw,935706000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,935706000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ahvg_p5oFkSFCUSlPfiGrg,us-gaap:StockholdersEquity,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ahvg_p5oFkSFCUSlPfiGrg,-10048000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10048000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fBvinuuylkqQHLwxb10qOA,us-gaap:StockholdersEquity,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fBvinuuylkqQHLwxb10qOA,-585756000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-585756000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2020_Tc5wFccKMk6MQw9t8Apbiw,us-gaap:StockholdersEquity,As_Of_12_31_2020_Tc5wFccKMk6MQw9t8Apbiw,341227000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,341227000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TmN7TqeJnkivguXGZQ_g7w,us-gaap:NetIncomeLoss,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TmN7TqeJnkivguXGZQ_g7w,-37763000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-37763000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,us-gaap:NetIncomeLoss,Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,-37763000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-37763000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,-176000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-176000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,-176000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-176000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4HWhD2Sc0ECxEVldtlW4TQ,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4HWhD2Sc0ECxEVldtlW4TQ,4062210,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,4062210.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4HWhD2Sc0ECxEVldtlW4TQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4HWhD2Sc0ECxEVldtlW4TQ,6000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qU-6oZJe6k65ePlp46LHfw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qU-6oZJe6k65ePlp46LHfw,529000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,529000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,535000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,535000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qU-6oZJe6k65ePlp46LHfw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qU-6oZJe6k65ePlp46LHfw,5334000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5334000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,5334000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5334000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kz1Exw9O7kKxznVxiU0tmg,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kz1Exw9O7kKxznVxiU0tmg,932817168,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,932817168.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kz1Exw9O7kKxznVxiU0tmg,us-gaap:StockholdersEquity,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kz1Exw9O7kKxznVxiU0tmg,1331000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1331000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_33tygzXCXkCqy3FmnDicVA,us-gaap:StockholdersEquity,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_33tygzXCXkCqy3FmnDicVA,941569000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,941569000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472vW0a8cUmKlIrsmlNkow,us-gaap:StockholdersEquity,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472vW0a8cUmKlIrsmlNkow,-10224000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10224000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tqF9giaG60aMZtfa8y4Bgw,us-gaap:StockholdersEquity,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tqF9giaG60aMZtfa8y4Bgw,-623519000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-623519000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2021_imAFffTnUUiRz0WokA4xqQ,us-gaap:StockholdersEquity,As_Of_3_31_2021_imAFffTnUUiRz0WokA4xqQ,309157000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,309157000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hxLpRMUICU66UUaG0U_hVQ,us-gaap:NetIncomeLoss,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hxLpRMUICU66UUaG0U_hVQ,-39068000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-39068000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:NetIncomeLoss,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,-39068000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-39068000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,-161000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-161000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,-161000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-161000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,350628,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,350628.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,1000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J1cmlDTwQEuUGbLXVKpGiA,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J1cmlDTwQEuUGbLXVKpGiA,42000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,42000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,43000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,43000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,3069330,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,3069330.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RImsCe2hPk2vBt2oCi44bQ,4000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J1cmlDTwQEuUGbLXVKpGiA,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J1cmlDTwQEuUGbLXVKpGiA,2515000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2515000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,2519000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2519000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J1cmlDTwQEuUGbLXVKpGiA,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J1cmlDTwQEuUGbLXVKpGiA,5449000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5449000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,5449000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5449000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ty8iBN4vpEWzToLpDcQ55A,us-gaap:CommonStockSharesOutstanding,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ty8iBN4vpEWzToLpDcQ55A,936237126,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,936237126.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-06-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ty8iBN4vpEWzToLpDcQ55A,us-gaap:StockholdersEquity,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ty8iBN4vpEWzToLpDcQ55A,1336000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1336000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kI-QPwvr1EaqzAp5zOhmPw,us-gaap:StockholdersEquity,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kI-QPwvr1EaqzAp5zOhmPw,949575000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,949575000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-31HUXEfREKf7jft3JhWPA,us-gaap:StockholdersEquity,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-31HUXEfREKf7jft3JhWPA,-10385000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10385000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1i8v-P_CqkS1ky6UIuHYoA,us-gaap:StockholdersEquity,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1i8v-P_CqkS1ky6UIuHYoA,-662587000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-662587000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_6_30_2021_lJRqOZLcfkKDO6i7Q9R_Hw,us-gaap:StockholdersEquity,As_Of_6_30_2021_lJRqOZLcfkKDO6i7Q9R_Hw,277939000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,277939000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_96nsSY3DwUCKtWzVrwEL8Q,us-gaap:NetIncomeLoss,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_96nsSY3DwUCKtWzVrwEL8Q,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_2,us-gaap:NetIncomeLoss,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__d1FSnXxIEmIEPSWR4i7Kw,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__d1FSnXxIEmIEPSWR4i7Kw,812694,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,812694.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__d1FSnXxIEmIEPSWR4i7Kw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__d1FSnXxIEmIEPSWR4i7Kw,1000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZuexQghksESIuWuNGazInA,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZuexQghksESIuWuNGazInA,128000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,128000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,129000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,129000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZuexQghksESIuWuNGazInA,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZuexQghksESIuWuNGazInA,10000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,10000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,10000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,10000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,287000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,287000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,287000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,287000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Other comprehensive gain (loss),Other comprehensive gain (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZuexQghksESIuWuNGazInA,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZuexQghksESIuWuNGazInA,5019000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5019000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,5019000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5019000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8PF-n6W9E22y0iOZExRhA,us-gaap:CommonStockSharesOutstanding,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8PF-n6W9E22y0iOZExRhA,937049820,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,937049820.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-09-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8PF-n6W9E22y0iOZExRhA,us-gaap:StockholdersEquity,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8PF-n6W9E22y0iOZExRhA,1337000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w37Z_oLdBEGz_im0uMGfeQ,us-gaap:StockholdersEquity,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w37Z_oLdBEGz_im0uMGfeQ,954732000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,954732000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cNOgpGnZK02S6FFNudhmSw,us-gaap:StockholdersEquity,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cNOgpGnZK02S6FFNudhmSw,-10098000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10098000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Mbllg07U70aOxgWFrVCfpg,us-gaap:StockholdersEquity,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Mbllg07U70aOxgWFrVCfpg,-704988000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-704988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,us-gaap:StockholdersEquity,As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,240983000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,240983000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ProfitLoss,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136206000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136206000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net loss,Net loss,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ProfitLoss,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119232000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119232000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net loss,Net loss,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:Depreciation,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,4009000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4009000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:Depreciation,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,4333000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4333000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:AdjustmentForAmortization,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,629000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,629000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ShareBasedCompensation,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,14294000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,14294000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ShareBasedCompensation,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,15802000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15802000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-2501000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-2501000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Unrealized foreign exchange gains,Unrealized foreign exchange gains,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-213000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-213000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Unrealized foreign exchange gains,Unrealized foreign exchange gains,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AmortizationAccretionOfMarketableSecurities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:AmortizationAccretionOfMarketableSecurities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,2165000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2165000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Amortization on available-for-sale debt securities,Amortization on available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AmortizationAccretionOfMarketableSecurities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,adap:AmortizationAccretionOfMarketableSecurities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,4094000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4094000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Amortization on available-for-sale debt securities,Amortization on available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,765000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,765000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,2239000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2239000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-29778000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-29778000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Increase in receivables and other operating assets,Increase in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-31809000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-31809000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Increase in receivables and other operating assets,Increase in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,15200000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15200000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Increase/(decrease) in payables and other current liabilities,Increase/(decrease) in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-109000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-109000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Increase/(decrease) in payables and other current liabilities,Increase/(decrease) in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-12388000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-12388000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,(Decrease)/increase in deferred revenue,(Decrease)/increase in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,1696000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1696000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,(Decrease)/increase in deferred revenue,(Decrease)/increase in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-143811000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-143811000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-123199000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-123199000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-26081000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-26081000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-4558000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-4558000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireIntangibleAssets_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:PaymentsToAcquireIntangibleAssets,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-231000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-231000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Acquisition of intangibles assets,Acquisition of intangibles assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireIntangibleAssets_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:PaymentsToAcquireIntangibleAssets,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-181000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-181000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Acquisition of intangibles assets,Acquisition of intangibles assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,136694000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,136694000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Maturity or redemption of marketable securities,Maturity or redemption of marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,190393000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,190393000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Maturity or redemption of marketable securities,Maturity or redemption of marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireMarketableSecurities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:PaymentsToAcquireMarketableSecurities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-42197000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42197000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Investment in marketable securities,Investment in marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireMarketableSecurities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:PaymentsToAcquireMarketableSecurities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-81363000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-81363000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Investment in marketable securities,Investment in marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,68185000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,68185000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net cash provided by investing activities,Net cash provided by investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,104291000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,104291000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net cash provided by investing activities,Net cash provided by investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,11422000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,11422000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,2529000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2529000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,42000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,42000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,707000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,707000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,11464000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,11464000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net cash provided by financing activities,Net cash provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,3236000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3236000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net cash provided by financing activities,Net cash provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-6791000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-6791000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-1177000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1177000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-70953000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-70953000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,"Net decrease in cash, cash equivalents and restricted cash","Net decrease in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-16849000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-16849000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,"Net decrease in cash, cash equivalents and restricted cash","Net decrease in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,151666000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,151666000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2020_Tc5wFccKMk6MQw9t8Apbiw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2020_Tc5wFccKMk6MQw9t8Apbiw,61484000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,61484000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2020-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,80713000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,80713000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,44635000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,44635000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2021-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NatureOfOperations_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NatureOfOperations,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 1 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> General</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of $880,052,000 as of September 30, 2022.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,General,General,Disclosures,http://www.adaptimmune.com/role/DisclosureGeneral,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_0,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,-880052000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-880052000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_1,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,-880052000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-880052000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 2 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Summary of Significant Accounting Policies </b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022 (the “Annual Report”). The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $79,001,000, marketable securities of $120,669,000 and restricted cash of $1,712,000 as of September 30, 2022. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has three customers, which are Genentech, Astellas and GSK. There were accounts receivable of $1,774,000 as of September 30, 2022 and $752,000 as of December 31, 2021. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no impairment losses have been recognized. As of September 30, 2022, there were no overdue accounts receivable.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(e)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">To be adopted in future periods</i> </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Measurement of credit losses on financial instruments</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for the fiscal year beginning January 1, 2020, including interim periods within that fiscal year. In November 2019, the FASB issued ASU 2019-10 which resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies (as defined by the SEC), including the Company, at that time to the fiscal year beginning January 1, 2023. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""/>In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. For public business entities, including the Company, the guidance is effective for fiscal years beginning on or after December 15, 2022, including interim periods within that fiscal year. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Summary of Significant Accounting Policies,Summary of Significant Accounting Policies,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_BasisOfAccountingPolicyPolicyTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:BasisOfAccountingPolicyPolicyTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2022 (the “Annual Report”). The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Basis of presentation,Basis of presentation,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_UseOfEstimates_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:UseOfEstimates,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Use of estimates in interim financial statements,Use of estimates in interim financial statements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_FairValueMeasurementPolicyPolicyTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:FairValueMeasurementPolicyPolicyTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $79,001,000, marketable securities of $120,669,000 and restricted cash of $1,712,000 as of September 30, 2022. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has three customers, which are Genentech, Astellas and GSK. There were accounts receivable of $1,774,000 as of September 30, 2022 and $752,000 as of December 31, 2021. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no impairment losses have been recognized. As of September 30, 2022, there were no overdue accounts receivable.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(e)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">To be adopted in future periods</i> </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Measurement of credit losses on financial instruments</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for the fiscal year beginning January 1, 2020, including interim periods within that fiscal year. In November 2019, the FASB issued ASU 2019-10 which resulted in the postponement of the effective date of the new guidance for eligible smaller reporting companies (as defined by the SEC), including the Company, at that time to the fiscal year beginning January 1, 2023. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""/>In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. For public business entities, including the Company, the guidance is effective for fiscal years beginning on or after December 15, 2022, including interim periods within that fiscal year. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,New accounting pronouncements,New accounting pronouncements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ConcentrationRiskCreditRisk_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ConcentrationRiskCreditRisk,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $79,001,000, marketable securities of $120,669,000 and restricted cash of $1,712,000 as of September 30, 2022. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has three customers, which are Genentech, Astellas and GSK. There were accounts receivable of $1,774,000 as of September 30, 2022 and $752,000 as of December 31, 2021. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no impairment losses have been recognized. As of September 30, 2022, there were no overdue accounts receivable.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Significant concentrations of credit risk,Significant concentrations of credit risk,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_0,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,79001000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,79001000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_1,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,79001000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,79001000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_0,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,120669000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,120669000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_1,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,120669000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,120669000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_0,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1712000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1712000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_1,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1712000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,1712000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfCustomers_As_Of_9_30_2022_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7jLLjClp6k2wLNlqjVEaHg,adap:NumberOfCustomers,As_Of_9_30_2022_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7jLLjClp6k2wLNlqjVEaHg,3,Unit_Standard_customer_EiEI5VB0-0ScVxXSlrEorg,INF,3.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Number of customers,Number of customers,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails,2022-09-30,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_9_30_2022_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7jLLjClp6k2wLNlqjVEaHg,us-gaap:AccountsReceivableNetCurrent,As_Of_9_30_2022_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7jLLjClp6k2wLNlqjVEaHg,1774000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,1774000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Accounts receivable, net of allowance for doubtful accounts of $0 and $0","Accounts receivable, net of allowance for doubtful accounts of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2021_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cPeeqXCjKkSZ6cEC_wv2Aw,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2021_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cPeeqXCjKkSZ6cEC_wv2Aw,752000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,752000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Accounts receivable, net of allowance for doubtful accounts of $0 and $0","Accounts receivable, net of allowance for doubtful accounts of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivable_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:AllowanceForDoubtfulAccountsReceivable,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Overdue accounts receivable,Overdue accounts receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:RevenueFromContractWithCustomerTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 3 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Revenue</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt 0pt 12pt 0pt;"">The Company had three revenue-generating contracts with customers in the three and nine months ended September 30, 2022 compared to two in the three and nine months ended September 30, 2021: a collaboration and license agreement with GSK, a collaboration agreement with Astellas and a strategic collaboration and license agreement with Genentech.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:28.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:28.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:32.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:18.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,007</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,203</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,120</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,732</p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,007</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,203</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 16,120</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,732</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Deferred revenue decreased by $46,567,000 from $199,422,000 at December 31, 2021 to $152,855,000 at September 30, 2022 primarily due to a $35,693,000 decrease caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.35 at December 31, 2021 to £1.00 to $1.11 at September 30, 2022. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">As of December 31, 2021, there was deferred revenue of $199,422,000 of which $13,038,000 was recognized as revenue in the nine months ended September 30, 2022.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of September 30, 2022 was $326,545,000. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Genentech Collaboration and License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Genentech agreement as of September 30, 2022 was $276,396,000. Of this amount $170,265,000 is allocated to the research services and rights granted for the initial ‘off-the-shelf’ collaboration targets, $88,016,000 is allocated to the research services and rights granted for the personalized therapies, $12,228,000 is allocated to the material rights to designate the additional ‘off-the-shelf’ collaboration targets, $4,710,000 is allocated to the material right for the first option to extend the research term and $1,177,000 is allocated to the material right for the option to extend the research term a second time. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company expects to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progresses and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expects to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options are exercised and then as development progresses, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expire. The Company expects to satisfy the performance obligations relating to the material rights to extend the research term from the point that the options are exercised and then over period of the extension, or at the point in time that the rights expire.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Astellas Collaboration Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Astellas agreement as of September 30, 2022 was $49,818,000, of which $12,337,000 is allocated to the rights granted for each of the two independent Astellas targets, $6,670,000 is allocated to research services and rights granted under the co-exclusive license for the first co-development target, $12,518,000 is allocated to research services and rights granted under the co-exclusive license for the second co-development target and $5,956,000 is allocated to research services and rights under the co-exclusive license for the third co-development targets. The Company expects to satisfy the performance obligations relating to the three co-development targets as development progresses and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company has determined that the performance obligations relating to the two independent Astellas targets would be recognized at a point-in-time, upon commencement of the licenses in the event of nomination of the target, since they are right-to-use licenses.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The GSK Collaboration and License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the GSK agreement as of September 30, 2022 was $330,000<span style=""white-space:pre-wrap;"">. The Company satisfies the performance obligations relating to the development of each target over time and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Future research, development, regulatory and sales milestones under each of the agreements are not considered probable as of September 30, 2022 and have not been included in the transaction price. Reimbursement of the research funding over the co-development period under the Astellas agreement is variable consideration and included in the transaction price as of September 30, 2022 to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. On October 24, 2022, the Company received notice of termination of the Collaboration and License Agreement, effective 60 days following the receipt of the notice of termination. As the terms of the transfer and related agreement are being negotiated, an estimate of the financial effect of this event cannot yet be made</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenue,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:NumberOfContractsWithCustomer,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,3,Unit_Standard_contract_4cLCNbpN10mf-VJ-9bKeqA,INF,3.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,adap:NumberOfContractsWithCustomer,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,3,Unit_Standard_contract_4cLCNbpN10mf-VJ-9bKeqA,INF,3.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,adap:NumberOfContractsWithCustomer,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,2,Unit_Standard_contract_4cLCNbpN10mf-VJ-9bKeqA,INF,2.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,adap:NumberOfContractsWithCustomer,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,2,Unit_Standard_contract_4cLCNbpN10mf-VJ-9bKeqA,INF,2.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DisaggregationOfRevenueTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:DisaggregationOfRevenueTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:28.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:28.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:32.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:18.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,007</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,203</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,120</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,732</p></td></tr><tr><td style=""vertical-align:bottom;width:34.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,007</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,203</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 16,120</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,732</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Summary of revenue categories,Summary of revenue categories,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_cH-7x65XDUOBNYicyW8c4A,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_cH-7x65XDUOBNYicyW8c4A,7007000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7007000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_dst0K66flUScBeIPNyuxuA,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_dst0K66flUScBeIPNyuxuA,1203000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1203000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_igOOiHX0cke8pT_ZF8SBcA,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_igOOiHX0cke8pT_ZF8SBcA,16120000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,16120000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_kIk4oBlXA0mJYDoiYLhgvQ,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_kIk4oBlXA0mJYDoiYLhgvQ,4732000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4732000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,7007000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7007000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,7007000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7007000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,1203000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1203000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,1203000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1203000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,16120000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,16120000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,16120000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,16120000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,4732000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4732000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,4732000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4732000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2021_To_12_31_2021_2_n_5Ge2LUaX2tSNNUwjPA,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2021_To_12_31_2021_2_n_5Ge2LUaX2tSNNUwjPA,46567000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,46567000.0,duration,2021-01-01,2021-12-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-12-31,(Decrease)/increase in deferred revenue,(Decrease)/increase in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:ContractWithCustomerLiability,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,152855000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,152855000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,35693000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,35693000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Amount of decrease in deferred income caused by the change in the exchange rate,Amount of decrease in deferred income caused by the change in the exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,1.35,Unit_Standard_pure_4wQqgPYYvEarxJpEPas59w,2,1.35,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1.11,Unit_Standard_pure_4wQqgPYYvEarxJpEPas59w,2,1.11,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA_0,us-gaap:ContractWithCustomerLiability,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,199422000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,199422000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA_1,us-gaap:ContractWithCustomerLiability,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,199422000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,199422000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityRevenueRecognized_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ContractWithCustomerLiabilityRevenueRecognized,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,13038000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,13038000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Revenue recognized in the period,Revenue recognized in the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,326545000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,326545000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_UQ1KF9bXrEuR8Yt9TcbDiQ,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_UQ1KF9bXrEuR8Yt9TcbDiQ,276396000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,276396000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_4_sVhSbyTkaCvMspdvx6-Q,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_4_sVhSbyTkaCvMspdvx6-Q,170265000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,170265000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_e-R-BohTcU6lXIDPin3Isw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_e-R-BohTcU6lXIDPin3Isw,88016000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,88016000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:ResearchServiceRightsGrantedForPersonalizedTherapiesMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_qoKBfAb8cE2XQhR6XkQBkg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_qoKBfAb8cE2XQhR6XkQBkg,12228000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,12228000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_MaterialRightForFirstOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_oThOkc1YT0CWy-A7NVEVCw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_MaterialRightForFirstOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_oThOkc1YT0CWy-A7NVEVCw,4710000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,4710000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:MaterialRightForFirstOptionExtendResearchTermMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_MaterialRightForSecondOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_ygoJ63Kc6EaV08p3U2q-Aw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_MaterialRightForSecondOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_ygoJ63Kc6EaV08p3U2q-Aw,1177000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,1177000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:MaterialRightForSecondOptionExtendResearchTermMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_G9Tax1dByEOsccnLdQIrpw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_G9Tax1dByEOsccnLdQIrpw,49818000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,49818000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_RightsGrantedFirstAndSecondIndependentTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_TDGfn33XTkWQt0zlWE1vjg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_RightsGrantedFirstAndSecondIndependentTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_TDGfn33XTkWQt0zlWE1vjg,12337000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,12337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:RightsGrantedFirstAndSecondIndependentTargetMember,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServicesAndRightsGrantedUnderCoExclusiveLicenseSecondTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_RhzscXwXe0C7MgmouFcw9g,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServicesAndRightsGrantedUnderCoExclusiveLicenseSecondTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_RhzscXwXe0C7MgmouFcw9g,6670000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,6670000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:ResearchServicesAndRightsGrantedUnderCoExclusiveLicenseSecondTargetMember,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServicesAndRightsUnderCoExclusiveLicenseSecondTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_S_5RzvejnEW4OUD5svHAiQ,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServicesAndRightsUnderCoExclusiveLicenseSecondTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_S_5RzvejnEW4OUD5svHAiQ,12518000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,12518000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:ResearchServicesAndRightsUnderCoExclusiveLicenseSecondTargetMember,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServicesAndRightsUnderCoExclusiveLicenseThirdTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0HZcUzNRq0Gmj3CAOc50sw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_srt_ProductOrServiceAxis_adap_ResearchServicesAndRightsUnderCoExclusiveLicenseThirdTargetMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_0HZcUzNRq0Gmj3CAOc50sw,5956000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,5956000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,adap:ResearchServicesAndRightsUnderCoExclusiveLicenseThirdTargetMember,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfCoDevelopmentTarget_Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7chOl_wpokCAiCKA_eGOQw,adap:NumberOfCoDevelopmentTarget,Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7chOl_wpokCAiCKA_eGOQw,3,Unit_Standard_item_dBeAMxkpM0uqlMu6JvCUKA,INF,3.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of co-development targets,Number of co-development targets,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfIndependentTargets_Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7chOl_wpokCAiCKA_eGOQw_0,adap:NumberOfIndependentTargets,Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7chOl_wpokCAiCKA_eGOQw,2,Unit_Standard_item_dBeAMxkpM0uqlMu6JvCUKA,INF,2.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of independent targets,Number of independent targets,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_NumberOfIndependentTargets_Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7chOl_wpokCAiCKA_eGOQw_1,adap:NumberOfIndependentTargets,Duration_1_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_7chOl_wpokCAiCKA_eGOQw,2,Unit_Standard_item_dBeAMxkpM0uqlMu6JvCUKA,INF,2.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of independent targets,Number of independent targets,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_OpOSuQdBtkCYBGeDcJN7gw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_9_30_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_OpOSuQdBtkCYBGeDcJN7gw,330000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,330000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Remaining performance obligation,Remaining performance obligation,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-09-30,None,None,None,adap:GSKCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:EarningsPerShareTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 4 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Loss per share</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following table reconciles the numerator and denominator in the basic and diluted loss per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:19.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:18.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net loss attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (41,421)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (42,401)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (136,206)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (119,232)</p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net loss attributable to ordinary shareholders used for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_O9qohHJxoUylrYjVtSaiAg;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (41,421)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_2pnROGgF8UeuWlXSWLXxcA;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (42,401)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_doQXAMWznUWMR34NJdsP-Q;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (136,206)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_dCDgLUD29UKd2zuvfy3gWQ;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (119,232)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic and diluted loss per share - Weighted average shares outstanding </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 980,791,114</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 936,600,648</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 961,354,122</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 933,992,708</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The dilutive effect of 152,427,845 and 115,924,296 stock options outstanding as of September 30, 2022 and 2021 respectively have been excluded from the diluted loss per share calculation for the three and nine months ended September 30, 2022 and 2021 because they would have an antidilutive effect on the loss per share for the period.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Loss per share,Loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShare,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following table reconciles the numerator and denominator in the basic and diluted loss per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:19.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:18.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net loss attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (41,421)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (42,401)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (136,206)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (119,232)</p></td></tr><tr><td style=""vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net loss attributable to ordinary shareholders used for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_O9qohHJxoUylrYjVtSaiAg;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (41,421)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_2pnROGgF8UeuWlXSWLXxcA;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (42,401)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_doQXAMWznUWMR34NJdsP-Q;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (136,206)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_dCDgLUD29UKd2zuvfy3gWQ;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (119,232)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic and diluted loss per share - Weighted average shares outstanding </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 980,791,114</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 936,600,648</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 961,354,122</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 933,992,708</p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of numerator and denominator in the basic and diluted loss per share computation,Schedule of numerator and denominator in the basic and diluted loss per share computation,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_3,us-gaap:NetIncomeLoss,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_3,us-gaap:NetIncomeLoss,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_2,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136206000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136206000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_2,us-gaap:NetIncomeLoss,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119232000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119232000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,-41421000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-41421000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Numerator for basic loss per share,Numerator for basic loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,-42401000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-42401000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Numerator for basic loss per share,Numerator for basic loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,-136206000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-136206000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Numerator for basic loss per share,Numerator for basic loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,-119232000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-119232000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Numerator for basic loss per share,Numerator for basic loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,980791114,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,980791114.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,980791114,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,980791114.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,936600648,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,936600648.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,936600648,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,936600648.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,961354122,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,961354122.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,961354122,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,961354122.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,933992708,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,933992708.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,933992708,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,933992708.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Denominator for basic loss per share - Weighted average shares outstanding,Denominator for basic loss per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_jglaqDhAeESd3T-zk0iaVA,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_jglaqDhAeESd3T-zk0iaVA,152427845,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,152427845.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSharesDetails,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_VrmNMohYLUO4tqCb5Asp2A,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_VrmNMohYLUO4tqCb5Asp2A,152427845,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,152427845.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSharesDetails,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_cR_zDvSeT0acC8w5VL_xxA,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_cR_zDvSeT0acC8w5VL_xxA,115924296,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,115924296.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSharesDetails,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_16ct-x91DUeNaehUblkPbA,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_16ct-x91DUeNaehUblkPbA,115924296,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,0,115924296.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSharesDetails,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNoteTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ComprehensiveIncomeNoteTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 5 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accumulated other comprehensive loss</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2022</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,785)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (357)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (11,142)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,792</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,792</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,808)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,808)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,155)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,155)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at March 31, 2022</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,801)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,512)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,313)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,694</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,694</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (39,108)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (39,108)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (316)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (316)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at June 30, 2022</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 785</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,828)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,043)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 58,011</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 58,011</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (50,489)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (50,489)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 204</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 204</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at September 30, 2022</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 8,307</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,624)</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 6,683</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:normal;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> gains (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2021</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,158)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 110</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,048)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,001)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,001)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,048</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,048</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (223)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (223)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at March 31, 2021</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,111)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (113)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,224)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,177)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,177)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,911</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,911</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 105</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 105</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at June 30, 2021</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,377)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (8)</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,385)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,564</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,564</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (15,310)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (15,310)</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 33</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 33</p></td></tr><tr><td style=""vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at September 30, 2021</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (10,123)</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 25</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (10,098)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Accumulated other comprehensive loss,Accumulated other comprehensive loss,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of changes in Accumulated other comprehensive (loss) income,Schedule of changes in Accumulated other comprehensive (loss) income,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_EpiGLoQL7U2VxtWZev4c5Q,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_EpiGLoQL7U2VxtWZev4c5Q,-10785000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10785000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_302r_MmHXke1Ho8_wDGreg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_302r_MmHXke1Ho8_wDGreg,-357000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-357000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xpdyzboj80-1MLt04NowCw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xpdyzboj80-1MLt04NowCw,-11142000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-11142000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-_NiHzdYWEmP39GcHPz2HQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-_NiHzdYWEmP39GcHPz2HQ,16792000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,16792000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,16792000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,16792000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-_NiHzdYWEmP39GcHPz2HQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-_NiHzdYWEmP39GcHPz2HQ,-13808000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-13808000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,-13808000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-13808000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2022_To_3_31_2022_ursWtt1qXUmUtsCEU53Gcg,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4RUEYPMuaUWp658BST8AwQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4RUEYPMuaUWp658BST8AwQ,-1155000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1155000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KWpSRSQAZEe6CbNoAICqKQ,-1155000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1155000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_OR1UV-UIdkKHlByb4fEsFw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_OR1UV-UIdkKHlByb4fEsFw,-7801000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-7801000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cmk5eq3Q5Uee1oirPSNpnA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cmk5eq3Q5Uee1oirPSNpnA,-1512000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1512000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rBxVXVUXwU-dJFJSuBY4NA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rBxVXVUXwU-dJFJSuBY4NA,-9313000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-9313000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_vL7WxqlerUiGx6j9i8uH7w,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_vL7WxqlerUiGx6j9i8uH7w,47694000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,47694000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,47694000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,47694000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_vL7WxqlerUiGx6j9i8uH7w,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_vL7WxqlerUiGx6j9i8uH7w,-39108000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-39108000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,-39108000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-39108000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_4_1_2022_To_6_30_2022_X3K31U9IKkOwYlqNy0PrXQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_Gm2F5_CsWEOqBMdYHELTbQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_Gm2F5_CsWEOqBMdYHELTbQ,-316000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-316000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4UbQtSeajE6bhe7pnCa0yA,-316000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-316000.0,duration,2022-04-01,2022-06-30,0001621227,http://www.sec.gov/CIK,duration_2022-04-01_2022-06-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nZdzZET5O0OdlqxuT5ENPw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nZdzZET5O0OdlqxuT5ENPw,785000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,785000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_EyeUf-KgGUSHqhk8ZGZF1g,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_EyeUf-KgGUSHqhk8ZGZF1g,-1828000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1828000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ypeqBfn63k2rbFsWXukkyQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ypeqBfn63k2rbFsWXukkyQ,-1043000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1043000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-06-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-06-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-tZua-XFQkO9-TcW6Buf5w,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-tZua-XFQkO9-TcW6Buf5w,58011000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,58011000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,58011000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,58011000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-tZua-XFQkO9-TcW6Buf5w,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_-tZua-XFQkO9-TcW6Buf5w,-50489000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-50489000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,-50489000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-50489000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_wCcDxK2P1UqDBw7rvEsn1w,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_wCcDxK2P1UqDBw7rvEsn1w,204000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,204000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TFWWCuiVskuESnEybWEJrg,204000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,204000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_LgBJ-HGgRUCnmqNpPp_Ovg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_LgBJ-HGgRUCnmqNpPp_Ovg,8307000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8307000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_Yzc7BzGtlEiY4QALO8bF8Q,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_Yzc7BzGtlEiY4QALO8bF8Q,-1624000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-1624000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IJMI7opmwEaMtYX99ZCnGQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IJMI7opmwEaMtYX99ZCnGQ,6683000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,6683000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_eyZ-i31Eh0aGxUlxsKImkg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_eyZ-i31Eh0aGxUlxsKImkg,-10158000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10158000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_-DJoZFaqikyzHooBBNhE7w,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_-DJoZFaqikyzHooBBNhE7w,110000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,110000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ahvg_p5oFkSFCUSlPfiGrg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ahvg_p5oFkSFCUSlPfiGrg,-10048000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10048000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2020-12-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2020-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nM8GnfAXSEydh6gGt2yOXQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nM8GnfAXSEydh6gGt2yOXQ,-3001000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-3001000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,-3001000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-3001000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nM8GnfAXSEydh6gGt2yOXQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nM8GnfAXSEydh6gGt2yOXQ,3048000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3048000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,3048000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3048000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2021_To_3_31_2021_GAw21rR3o02O2BeaTn54sA,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_freS4hJAqEmD2MPdOx6wpw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_freS4hJAqEmD2MPdOx6wpw,-223000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-223000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccWTLHKxy0iW4o75uIH7Aw,-223000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-223000.0,duration,2021-01-01,2021-03-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_3KuiWSNx10i4ZE-ZI29Viw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_3KuiWSNx10i4ZE-ZI29Viw,-10111000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10111000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_wlypAWIS0EyHaW5Qhl84JA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_wlypAWIS0EyHaW5Qhl84JA,-113000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-113000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472vW0a8cUmKlIrsmlNkow,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472vW0a8cUmKlIrsmlNkow,-10224000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10224000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-03-31,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_c3Irzhr310S38lRRw-hiTg,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_c3Irzhr310S38lRRw-hiTg,-4177000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-4177000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,-4177000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-4177000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_c3Irzhr310S38lRRw-hiTg,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_c3Irzhr310S38lRRw-hiTg,3911000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3911000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,3911000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3911000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_4_1_2021_To_6_30_2021_ygwLPZx68UuVkEGNY_njdQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_YJj_ShDi40ewGU56ZnSlkQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_YJj_ShDi40ewGU56ZnSlkQ,105000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,105000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6-9dwYUS2kuooM6koIxUEA,105000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,105000.0,duration,2021-04-01,2021-06-30,0001621227,http://www.sec.gov/CIK,duration_2021-04-01_2021-06-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_ijw4HV_UNkSCLENbpLBB-w,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_ijw4HV_UNkSCLENbpLBB-w,-10377000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10377000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember__eB7-OZNZUqQPYsiRSNNIA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember__eB7-OZNZUqQPYsiRSNNIA,-8000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-8000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-31HUXEfREKf7jft3JhWPA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-31HUXEfREKf7jft3JhWPA,-10385000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10385000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-06-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-06-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_CgF6DQIWgEOTV3LjC-XI4Q,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_CgF6DQIWgEOTV3LjC-XI4Q,15564000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15564000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,15564000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15564000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, tax","Foreign currency gains on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_CgF6DQIWgEOTV3LjC-XI4Q,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_CgF6DQIWgEOTV3LjC-XI4Q,-15310000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-15310000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,-15310000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-15310000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,0,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,0.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_J6t6M2DAWEOXqmZx7oaaSw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_J6t6M2DAWEOXqmZx7oaaSw,33000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,33000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_209D8NMwCU6ctMphqyjOug,33000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,33000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_diOvpH5kHk-mzvO_FRsA5A,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_diOvpH5kHk-mzvO_FRsA5A,-10123000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10123000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_dZjc-ROTmk2BSofUNy53iw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_dZjc-ROTmk2BSofUNy53iw,25000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,25000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cNOgpGnZK02S6FFNudhmSw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cNOgpGnZK02S6FFNudhmSw,-10098000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,-10098000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Accumulated other comprehensive income (loss),Accumulated other comprehensive income (loss),BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-09-30,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_FairValueDisclosuresTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:FairValueDisclosuresTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 6 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of September 30, 2022 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 97,771</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 97,771</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 120,669</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 97,771</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,898</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurements,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of September 30, 2022 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 97,771</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 97,771</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 120,669</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 97,771</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,898</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_d8xAt1e150KPRrRTwVNB1g,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_d8xAt1e150KPRrRTwVNB1g,97771000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,97771000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_xOLjBxX_mEejlpMZL7gFbA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_xOLjBxX_mEejlpMZL7gFbA,97771000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,97771000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_-sEXZk7niEi7qgZOLbJGtA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_-sEXZk7niEi7qgZOLbJGtA,18066000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,18066000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_8OddvLRLTU2EA_DXH_me5g,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_8OddvLRLTU2EA_DXH_me5g,18066000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,18066000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5F3eL_7XakaGkSAwssNvew,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5F3eL_7XakaGkSAwssNvew,4832000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4832000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_BeYuWLBWd0-ru6qN1e5vYw,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_BeYuWLBWd0-ru6qN1e5vYw,4832000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4832000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GEcjLz8V4U6hsY9ofzyVKA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GEcjLz8V4U6hsY9ofzyVKA,120669000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,120669000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3CEtEuZcHkGYdqx4ryDUeQ,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_3CEtEuZcHkGYdqx4ryDUeQ,97771000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,97771000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_S3DEt5AGG0O_dmE5a-IL9w,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_9_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_S3DEt5AGG0O_dmE5a-IL9w,22898000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,22898000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 7 — Marketable securities – available-for-sale debt securities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of September 30, 2022, the Company has the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,410</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (43)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,367</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,117</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (51)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,000</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (168)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 84,319</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,277)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 83,042</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">1 year to 2 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,447</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (85)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,362</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 122,293</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,624)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 120,669</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of September 30, 2022 and December 31, 2021 are as follows: </p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, 2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for 12 months or longer:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 34,519</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (393)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,232</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (35)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 63,252</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 14</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,012)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 163,258</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 34</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (348)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (51)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">—</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bond</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (168)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,993</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 120,669</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 24</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,624)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 176,483</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 36</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (390)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of September 30, 2022, the securities in an unrealized loss position are not considered to be other than temporarily impaired because the impairments are not severe and have been for a short duration. Six securities have been in an unrealized loss position for more than one year with a net total unrealized loss of $393,000. Furthermore, the Company does not intend to sell the debt securities in an unrealized loss position, believes that it has the ability to hold the debt securities to maturity, and it is currently unlikely that the Company will be required to sell these securities before the recovery of the amortized cost.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of September 30, 2022, the Company has the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,410</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (43)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,367</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,117</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (51)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,000</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (168)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 84,319</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,277)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 83,042</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">1 year to 2 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,447</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (85)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,362</p></td></tr><tr><td style=""vertical-align:bottom;width:40.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 122,293</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,624)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 120,669</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of marketable securities,Schedule of marketable securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_9vgNN3kNgEuDpOuvMl5m3A,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_9vgNN3kNgEuDpOuvMl5m3A,P3M,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,srt:MaximumMember,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_Gv_UJMqXu0CqpSsdSGyClw,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_Gv_UJMqXu0CqpSsdSGyClw,12410000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,12410000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_Gv_UJMqXu0CqpSsdSGyClw,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_Gv_UJMqXu0CqpSsdSGyClw,43000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,43000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_Gv_UJMqXu0CqpSsdSGyClw,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_Gv_UJMqXu0CqpSsdSGyClw,12367000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,12367000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_MocCjCzJO0qbk92XzPTibg,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_MocCjCzJO0qbk92XzPTibg,P3M,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,srt:MaximumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_zapRIWEv4EWavqldegTrtA,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_zapRIWEv4EWavqldegTrtA,18117000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,18117000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_zapRIWEv4EWavqldegTrtA,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_zapRIWEv4EWavqldegTrtA,51000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,51000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_zapRIWEv4EWavqldegTrtA,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_zapRIWEv4EWavqldegTrtA,18066000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,18066000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_6Srjsu0gOUOKs5QnvejcpA,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_6Srjsu0gOUOKs5QnvejcpA,P3M,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,srt:MinimumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_zd6K_7HZl0ORq5GtZf4VdQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_zd6K_7HZl0ORq5GtZf4VdQ,P1Y,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,srt:MaximumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_hCWZOXo-mkGtYLVOJn7asQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_hCWZOXo-mkGtYLVOJn7asQ,5000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_hCWZOXo-mkGtYLVOJn7asQ,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_hCWZOXo-mkGtYLVOJn7asQ,168000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,168000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_hCWZOXo-mkGtYLVOJn7asQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_hCWZOXo-mkGtYLVOJn7asQ,4832000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4832000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_p9lhHWcZgkyvlTgIBxVh0Q,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_p9lhHWcZgkyvlTgIBxVh0Q,P3M,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,srt:MinimumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember__Zn2V5tpPUGFrgg3kuwXuA,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember__Zn2V5tpPUGFrgg3kuwXuA,P1Y,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,srt:MaximumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_wCz8yDH-2UmFxScvbpjwtg,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_wCz8yDH-2UmFxScvbpjwtg,84319000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,84319000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_wCz8yDH-2UmFxScvbpjwtg,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_wCz8yDH-2UmFxScvbpjwtg,1277000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1277000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_wCz8yDH-2UmFxScvbpjwtg,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_wCz8yDH-2UmFxScvbpjwtg,83042000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,83042000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_lKGDuHgXB0euXJmt8UQYyQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_lKGDuHgXB0euXJmt8UQYyQ,P1Y,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember,None,srt:MinimumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember__ZExvD2CQU6RcaSk9Nz84g,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember__ZExvD2CQU6RcaSk9Nz84g,P2Y,None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember,None,srt:MaximumMember,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_WNPRdd5ZAEifK32aq3CtIQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_WNPRdd5ZAEifK32aq3CtIQ,2447000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2447000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_WNPRdd5ZAEifK32aq3CtIQ,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_WNPRdd5ZAEifK32aq3CtIQ,85000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,85000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_WNPRdd5ZAEifK32aq3CtIQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember_WNPRdd5ZAEifK32aq3CtIQ,2362000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2362000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodOneYearToTwoYearsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_VdicQb4_306WQxvK5rHDxQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_VdicQb4_306WQxvK5rHDxQ,122293000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,122293000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_VdicQb4_306WQxvK5rHDxQ,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_VdicQb4_306WQxvK5rHDxQ,1624000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1624000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_VdicQb4_306WQxvK5rHDxQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_9_30_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_VdicQb4_306WQxvK5rHDxQ,120669000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,120669000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of September 30, 2022 and December 31, 2021 are as follows: </p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, 2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for 12 months or longer:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 34,519</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (393)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,232</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (35)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 63,252</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 14</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,012)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 163,258</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 34</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (348)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,066</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (51)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">—</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bond</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,832</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (168)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,993</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 120,669</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 24</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,624)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 176,483</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 36</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (390)</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position,Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,18066000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,18066000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,-3,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-3.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,51000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,51000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_rehXSgaekEiHT_57ABs0Kw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_rehXSgaekEiHT_57ABs0Kw,4832000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4832000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_rehXSgaekEiHT_57ABs0Kw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_rehXSgaekEiHT_57ABs0Kw,-1,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-1.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_rehXSgaekEiHT_57ABs0Kw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_rehXSgaekEiHT_57ABs0Kw,168000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,168000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_qEVG6dN27ESqttEdcXKHPg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_qEVG6dN27ESqttEdcXKHPg,4993000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4993000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_qEVG6dN27ESqttEdcXKHPg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_qEVG6dN27ESqttEdcXKHPg,-1,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-1.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_qEVG6dN27ESqttEdcXKHPg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_qEVG6dN27ESqttEdcXKHPg,7000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_WFKBoKxKckGK-RUpJ3o-Rg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_WFKBoKxKckGK-RUpJ3o-Rg,120669000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,120669000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_WFKBoKxKckGK-RUpJ3o-Rg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_WFKBoKxKckGK-RUpJ3o-Rg,-24,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-24.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_WFKBoKxKckGK-RUpJ3o-Rg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_WFKBoKxKckGK-RUpJ3o-Rg,1624000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1624000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_rmPiHk-sdE-5NRTl7fJJRg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_rmPiHk-sdE-5NRTl7fJJRg,176483000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,176483000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_rmPiHk-sdE-5NRTl7fJJRg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_rmPiHk-sdE-5NRTl7fJJRg,-36,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-36.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_rmPiHk-sdE-5NRTl7fJJRg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_rmPiHk-sdE-5NRTl7fJJRg,390000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,390000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,-6,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-6.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember__644O63eN0WOl4Hbq9HNvQ,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember__644O63eN0WOl4Hbq9HNvQ,-1,Unit_Standard_security_JU-rU4h_JU613WJ2BDN3aw,INF,-1.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2021-12-31,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss,As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_cgQFniT770m0F_QyVJzI5Q,393000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,393000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,"Unrealized losses, 12 months or longer","Unrealized losses, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-09-30,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherCurrentAssetsTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:OtherCurrentAssetsTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 8 — Other current assets</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Other current assets consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate tax receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 48,543</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 30,773</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,052</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,043</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,171</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 746</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,217</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,482</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,712</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,082</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 62,695</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,126</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Other current assets consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate tax receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 48,543</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 30,773</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,052</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,043</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,171</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 746</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,217</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,482</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,712</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,082</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 62,695</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,126</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Summary of other current assets,Summary of other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxesReceivable_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:IncomeTaxesReceivable,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,48543000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,48543000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Corporate tax receivable,Corporate tax receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxesReceivable_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:IncomeTaxesReceivable,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,30773000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,30773000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Corporate tax receivable,Corporate tax receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:PrepaidExpenseCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,8052000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8052000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:PrepaidExpenseCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,9043000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,9043000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,adap:ClinicalMaterialsCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1171000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1171000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,adap:ClinicalMaterialsCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,746000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,746000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,3217000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3217000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,2482000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2482000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OtherAssetsCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1712000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1712000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OtherAssetsCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,2082000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2082000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,62695000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,62695000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,45126000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,45126000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeasesTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:LesseeOperatingLeasesTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 9 — Operating leases</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has operating leases in relation to property for office and research facilities<span style=""font-size:12pt;"">. </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On March 30, 2022, the Company entered into an agreement to modify the lease of 39 Innovation Drive, Milton Park, Abingdon, Oxfordshire, UK, and on June 15, 2022, the deeds associated with the modification were signed. However, for purposes of ASC 842 <i style=""font-style:italic;"">Leases, </i>the Company determined that the effective date of the modification is March 30, 2022. The effect of the modification was a partial reduction of the scope of the lease and an increase in contractual lease payments relating to a non-lease component. The modification did not result in the identification of a separate contract but did result in the identification of a non-lease component relating to a leasehold improvement. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Upon modification, the lease liability has been remeasured using the current estimate of the Company’s incremental borrowing rate. The remeasurement of the lease liability also resulted in variable lease payments not previously included in the amount of the lease liability becoming included in the amount of the lease payments as at the date of the modification. The amount of the remeasurement of the lease liability due to the inclusion of variable lease payments that depend on an index or rate has been recognized as an adjustment to the corresponding right-of-use asset. The effect of the modification was to increase the lease liability and the corresponding right-of-use asset by $75,000.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the weighted-average remaining lease term and the weighted-average discount rate as at September 30, 2022 and 2021:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">7.0 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">8.0 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of September 30, 2022 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2022</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,010</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,833</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,782</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,829</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,883</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,004</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 28,341</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,941)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,400</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maximum lease term without activation of termination options is to 2041. </p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Operating leases,Operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeases,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AmountOfIncreaseDecreaseInObligationAndRightOfUseAssetForOperatingLeaseFollowingLeaseModification_Duration_3_30_2022_To_3_30_2022_cplEiFI5UEKx2Q-TdXvIhA,adap:AmountOfIncreaseDecreaseInObligationAndRightOfUseAssetForOperatingLeaseFollowingLeaseModification,Duration_3_30_2022_To_3_30_2022_cplEiFI5UEKx2Q-TdXvIhA,75000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,75000.0,duration,2022-03-30,2022-03-30,0001621227,http://www.sec.gov/CIK,duration_2022-03-30_2022-03-30,Amount of increase (decrease) in obligation and right-of-use asset for operating lease following lease modification,Amount of increase (decrease) in obligation and right-of-use asset for operating lease following lease modification,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the weighted-average remaining lease term and the weighted-average discount rate as at September 30, 2022 and 2021:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">7.0 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">8.0 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of weighted-average remaining lease term and the weighted-average discount rate,Schedule of weighted-average remaining lease term and the weighted-average discount rate,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">7.0 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">8.0 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of maturities of operating lease liabilities,Schedule of maturities of operating lease liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,P7Y,None,None,,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,P8Y,None,None,,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2021-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,0.068,Unit_Standard_pure_4wQqgPYYvEarxJpEPas59w,3,0.068,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_9_30_2021_dleCFxItAE6VYecoSAl3Gw,0.068,Unit_Standard_pure_4wQqgPYYvEarxJpEPas59w,3,0.068,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-09-30,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2021-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1010000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1010000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,2022,2022,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,3833000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3833000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,2023,2023,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,3782000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3782000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,2024,2024,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,3829000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3829000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,2025,2025,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,3883000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3883000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,2026,2026,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,12004000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,12004000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,after 2026,after 2026,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,28341000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,28341000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Total lease payments,Total lease payments,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,5941000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5941000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Less: Imputed interest,Less: Imputed interest,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiability_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OperatingLeaseLiability,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,22400000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,22400000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Present value of lease liability,Present value of lease liability,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 10 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accrued expenses and other current liabilities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:17.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 19,526</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 13,436</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 10,356</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,758</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,067</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,388</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,130</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 327</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 36,079</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 29,909</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:17.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 19,526</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 13,436</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 10,356</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,758</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,067</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,388</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,130</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 327</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.72%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 36,079</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:3.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 29,909</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Schedule of accrued expenses and other current liabilities,Schedule of accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,19526000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,19526000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,13436000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,13436000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,10356000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,10356000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,11758000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,11758000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,5067000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5067000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,4388000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,4388000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,us-gaap:OtherLiabilitiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,1130000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1130000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,us-gaap:OtherLiabilitiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,327000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,327000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,36079000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,36079000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_9_30_2022_bCynnPhNUkuhYrnqKzcO2w,36079000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,36079000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-09-30,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,29909000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,29909000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2021_ymWNUVk2MUOtjoc1s1QfJA,29909000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,29909000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:CommitmentsAndContingenciesDisclosureTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 11 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Contingencies and commitments</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Alpine Collaboration Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On May 14, 2019, the Company entered into a Collaboration Agreement relating to the development of next-generation SPEAR T-cell products with Alpine. The Company paid an upfront exclusive license option fee of $2,000,000 to Alpine in June 2019. Under the agreement, Adaptimmune will pay Alpine for ongoing research and development funding costs and development and commercialization milestone payments up to a maximum of $288,000,000 may be payable if all possible targets are selected and milestones achieved. The upfront payment of $2,000,000 and the payments for ongoing research was recognized within Research and development in the Consolidated Statement of Operations for the year ended December 31, 2019. A further payment of $1,000,000 was paid and recognized within Research and development in the Consolidated Statement of Operations for the nine months ended September 30, 2022. Alpine would also receive low single-digit royalties on worldwide net sales of applicable products.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Universal Cells Research, Collaboration and License Agreement and </i><i style=""font-style:italic;"">Co-development and Co-commercialization agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On November 25, 2015, the Company entered into a Research, Collaboration and License Agreement relating to gene editing and Human Leukocyte Antigen (“HLA”) engineering technology with Universal Cells, Inc. (“Universal Cells”). The Company paid an upfront license and start-up fee of $2,500,000 to Universal Cells in November 2015, a milestone payment of $3,000,000 in February 2016 and </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">further milestone payments of $200,000 and $900,000 were made in the years ended December 31, 2018 and 2017, respectively. The agreement was amended and re-stated as of January 13, 2020, primarily to reflect changes to the development plan agreed between the parties. The agreement was further amended as of July 22, 2022, primarily to make certain changes to development milestones and to agree on the status thereof, as agreed between the parties. Following the amendment, a milestone payment of $500,000 was made in the nine months ended 30 September 2022. Further milestone payments of up to $35,300,000 are payable if certain development and product milestones are achieved of which a milestone of $1,800,000 has been accrued but not paid as of September 30, 2022, and milestones of $600,000 and $400,000 have been invoiced, but not yet paid, as of September 30, 2022. Universal Cells would also receive a profit-share payment for the first product, and royalties on sales of other products utilizing its technology. The upfront license and start-up fee and milestone payments were expensed to Research and development when incurred.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">MD Anderson Strategic Alliance</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On September 26, 2016, the Company announced that it had entered into a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center (“MD Anderson”) designed to expedite the development of T-cell therapies for multiple types of cancer. The Company and MD Anderson are collaborating on a number of studies including clinical and preclinical development of the Company’s SPEAR T-cell therapies and will collaborate on future clinical stage first and second generation SPEAR T-cell therapies across a number of cancers.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Under the terms of the agreement, the Company committed at least $19,644,000 to fund studies. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance and the performance of set milestones by MD Anderson. The Company made an upfront payment of $3,412,000 to MD Anderson in the year ended December 31, 2017 and milestone payments of $2,326,000, $3,549,000 and $454,000 in the years ended December 31, 2018, 2020, and 2021, respectively. A further milestone of $2,326,000 was met and paid in the nine months ended September 30, 2022. The Company is obligated to make further payments to MD Anderson as certain milestones are achieved. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, amongst other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Contingencies and commitments,Contingencies and commitments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitments,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestoneAmountPayable_As_Of_6_30_2019_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_z8Ze7smkb0u0w7yLYpGmvA,adap:LicenseAgreementMilestoneAmountPayable,As_Of_6_30_2019_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_z8Ze7smkb0u0w7yLYpGmvA,288000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,288000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2019-06-30,Potential milestone payments,Potential milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsAlpineCollaborationAgreementDetails,2019-06-30,None,None,None,None,None,None,None,None,srt:MaximumMember,None,adap:AlpineImmuneSciencesInc.Member,us-gaap:ResearchAndDevelopmentExpenseMember,adap:CollaborationAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementUpfrontLicenseFees_Duration_6_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_4ZOJCJsOWES-i3Etq682Ag_0,adap:LicenseAgreementUpfrontLicenseFees,Duration_6_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_4ZOJCJsOWES-i3Etq682Ag,2000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,2000000.0,duration,2019-06-01,2019-06-30,0001621227,http://www.sec.gov/CIK,duration_2019-06-01_2019-06-30,Upfront license fees,Upfront license fees,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsAlpineCollaborationAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:AlpineImmuneSciencesInc.Member,us-gaap:ResearchAndDevelopmentExpenseMember,adap:CollaborationAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementUpfrontLicenseFees_Duration_6_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_4ZOJCJsOWES-i3Etq682Ag_1,adap:LicenseAgreementUpfrontLicenseFees,Duration_6_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_4ZOJCJsOWES-i3Etq682Ag,2000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,2000000.0,duration,2019-06-01,2019-06-30,0001621227,http://www.sec.gov/CIK,duration_2019-06-01_2019-06-30,Upfront license fees,Upfront license fees,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsAlpineCollaborationAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:AlpineImmuneSciencesInc.Member,us-gaap:ResearchAndDevelopmentExpenseMember,adap:CollaborationAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_nho26vHGaUu1BzF4gd5oaw,adap:LicenseAgreementMilestonePayments,Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_adap_AlpineImmuneSciencesInc.Member_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAgreementMember_nho26vHGaUu1BzF4gd5oaw,1000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,1000000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:AlpineImmuneSciencesInc.Member,us-gaap:ResearchAndDevelopmentExpenseMember,adap:CollaborationAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementUpfrontLicenseAndStartUpFees_Duration_11_1_2015_To_11_30_2015_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_AF5SYywWzUysPq-25DDsjg,adap:LicenseAgreementUpfrontLicenseAndStartUpFees,Duration_11_1_2015_To_11_30_2015_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_AF5SYywWzUysPq-25DDsjg,2500000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,2500000.0,duration,2015-11-01,2015-11-30,0001621227,http://www.sec.gov/CIK,duration_2015-11-01_2015-11-30,Upfront license and start-up fees,Upfront license and start-up fees,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_2_1_2016_To_2_29_2016_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_TpYOshF760KXPZs8g9-sVA,adap:LicenseAgreementMilestonePayments,Duration_2_1_2016_To_2_29_2016_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_TpYOshF760KXPZs8g9-sVA,3000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,3000000.0,duration,2016-02-01,2016-02-29,0001621227,http://www.sec.gov/CIK,duration_2016-02-01_2016-02-29,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3BEUQ2uR5EyIT-WB5CH4Vg,adap:LicenseAgreementMilestonePayments,Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3BEUQ2uR5EyIT-WB5CH4Vg,200000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,200000.0,duration,2018-01-01,2018-12-31,0001621227,http://www.sec.gov/CIK,duration_2018-01-01_2018-12-31,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_XZPHpYo950-nzZMHl6ygVQ,adap:LicenseAgreementMilestonePayments,Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_XZPHpYo950-nzZMHl6ygVQ,900000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,900000.0,duration,2017-01-01,2017-12-31,0001621227,http://www.sec.gov/CIK,duration_2017-01-01_2017-12-31,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_vIKq-Zgl4EeCEmF9u_JgZA,adap:LicenseAgreementMilestonePayments,Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_vIKq-Zgl4EeCEmF9u_JgZA,500000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,500000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestoneAmountPayable_As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3n-gB5_8kk20ZzF0B-M0gA,adap:LicenseAgreementMilestoneAmountPayable,As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3n-gB5_8kk20ZzF0B-M0gA,35300000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,35300000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Potential milestone payments,Potential milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsAlpineCollaborationAgreementDetails,2022-09-30,None,None,None,None,None,None,None,None,srt:MaximumMember,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentAccruedButNotYetPaid_As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3n-gB5_8kk20ZzF0B-M0gA,adap:LicenseAgreementMilestonePaymentAccruedButNotYetPaid,As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3n-gB5_8kk20ZzF0B-M0gA,1800000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,1800000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Milestone payment accrued but not yet paid,Milestone payment accrued but not yet paid,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsAlpineCollaborationAgreementDetails,2022-09-30,None,None,None,None,None,None,None,None,srt:MaximumMember,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentInvoicedButNotYetPaid_As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3n-gB5_8kk20ZzF0B-M0gA,adap:LicenseAgreementMilestonePaymentInvoicedButNotYetPaid,As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_3n-gB5_8kk20ZzF0B-M0gA,600000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,600000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Milestone payment invoiced but not paid,Milestone payment invoiced but not paid,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,2022-09-30,None,None,None,None,None,None,None,None,srt:MaximumMember,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentInvoicedButNotYetPaid_As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_OaaHlbjVIUGWdm0H_bDPHg,adap:LicenseAgreementMilestonePaymentInvoicedButNotYetPaid,As_Of_9_30_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_OaaHlbjVIUGWdm0H_bDPHg,400000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,400000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-09-30,Milestone payment invoiced but not paid,Milestone payment invoiced but not paid,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,2022-09-30,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,None,adap:CollaborationAndLicenseAgreementMember,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_MilestoneAmountPayable_As_Of_9_26_2016_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_srt_RangeAxis_srt_MinimumMember_fpDdsRLW4E2PrvpTcFo64Q,adap:MilestoneAmountPayable,As_Of_9_26_2016_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_srt_RangeAxis_srt_MinimumMember_fpDdsRLW4E2PrvpTcFo64Q,19644000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,19644000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2016-09-26,Potential milestone payments,Potential milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,2016-09-26,None,None,None,None,None,None,None,None,srt:MinimumMember,None,adap:MDAndersonStrategicAllianceMember,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_UpfrontPayment_Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_vw1a6ZTDNkKdYltPZyeL_w,adap:UpfrontPayment,Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_vw1a6ZTDNkKdYltPZyeL_w,3412000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,3412000.0,duration,2017-01-01,2017-12-31,0001621227,http://www.sec.gov/CIK,duration_2017-01-01_2017-12-31,Upfront payment,Upfront payment,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_oqTLshppqEO6xHblviMtdQ,adap:MilestonePayments,Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_oqTLshppqEO6xHblviMtdQ,2326000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,2326000.0,duration,2018-01-01,2018-12-31,0001621227,http://www.sec.gov/CIK,duration_2018-01-01_2018-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_SOyWbXDu7ke8Qc5IgGTbHA,adap:MilestonePayments,Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_SOyWbXDu7ke8Qc5IgGTbHA,3549000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,3549000.0,duration,2020-01-01,2020-12-31,0001621227,http://www.sec.gov/CIK,duration_2020-01-01_2020-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_wrsbYD2W7EuTrGf9hzDPkA,adap:MilestonePayments,Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_wrsbYD2W7EuTrGf9hzDPkA,454000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,454000.0,duration,2021-01-01,2021-12-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_MilestonePaymentMetAndPaid_Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_7Xi3lewXbkOIvsRu6mRNVg,adap:MilestonePaymentMetAndPaid,Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_7Xi3lewXbkOIvsRu6mRNVg,2326000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,2326000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Milestone met and paid in current period,Milestone met and paid in current period,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 12 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Share-based compensation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 447</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,177</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,003</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,064</p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">General and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,216</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,842</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,291</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,738</p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,663</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,019</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 14,294</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 15,802</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5,996,581</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">4,170,230</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">30,608,533</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">19,891,334</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.21</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.51</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.37</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.70</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">1,866,216</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">1,348,920</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">22,916,376</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">16,008,168</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.28</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.70</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.53</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.98</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Share-based compensation,Share-based compensation,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 447</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,177</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,003</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,064</p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">General and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,216</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,842</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,291</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,738</p></td></tr><tr><td style=""vertical-align:bottom;width:50.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,663</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,019</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 14,294</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 15,802</b></p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Summary of share-based compensation expense included in the unaudited consolidated statements of operations,Summary of share-based compensation expense included in the unaudited consolidated statements of operations,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XuQwpY6_PE23uKQJufXINQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XuQwpY6_PE23uKQJufXINQ,447000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,447000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_hjkBnYA2jEW2Skp2iDTo9A,us-gaap:AllocatedShareBasedCompensationExpense,Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_hjkBnYA2jEW2Skp2iDTo9A,2177000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2177000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_OeXUDlxE2EawzrWlpLBN_A,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_OeXUDlxE2EawzrWlpLBN_A,5003000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5003000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ts_yRCdKn0S1Zbl2gQDBwg,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ts_yRCdKn0S1Zbl2gQDBwg,7064000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,7064000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2sMeWY7Klkymm1Jn8ZprYw,us-gaap:AllocatedShareBasedCompensationExpense,Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_2sMeWY7Klkymm1Jn8ZprYw,3216000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3216000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JvQD1WzGiEysMxO8OAmnzQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JvQD1WzGiEysMxO8OAmnzQ,2842000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,2842000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4PuYi2C9SUiVZaS3r_9yrw,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4PuYi2C9SUiVZaS3r_9yrw,9291000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,9291000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r_o_DtQDVUmpePvCkYSZRQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r_o_DtQDVUmpePvCkYSZRQ,8738000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,8738000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,3663000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,3663000.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,5019000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,5019000.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,14294000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,14294000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,15802000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-3,15802000.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Nine months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:21.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">September 30, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2021</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5,996,581</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">4,170,230</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">30,608,533</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">19,891,334</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.21</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.51</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.37</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.70</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">1,866,216</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">1,348,920</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">22,916,376</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">16,008,168</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:50.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.28</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.70</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.53</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.98</p></td></tr></table>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Summary of all stock option activity,Summary of all stock option activity,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,5996581,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,5996581.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,4170230,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,4170230.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,30608533,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,30608533.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,19891334,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,19891334.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,0.21,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.21,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,0.51,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.51,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,0.37,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.37,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,0.70,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.7,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,1866216,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,1866216.0,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,1348920,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,1348920.0,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,22916376,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,22916376.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,16008168,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,16008168.0,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_7_1_2022_To_9_30_2022_Y_p8nqg2okKFZZhuP9asBQ,0.28,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.28,duration,2022-07-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-07-01_2022-09-30,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_7_1_2021_To_9_30_2021_MgY8-Vskl0SIeUmkUivzaQ,0.70,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.7,duration,2021-07-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-07-01_2021-09-30,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,0.53,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.53,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2021_To_9_30_2021_oGZhbXPaHEuox9G53piZ1A,0.98,Unit_Divide_USD_shares_36T9eNllhE6rZXOYNcELnQ,2,0.98,duration,2021-01-01,2021-09-30,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-09-30,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquityNoteDisclosureTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:StockholdersEquityNoteDisclosureTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 13 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Stockholders’ equity</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On August 10, 2020 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) (the “Sales Agreement”) under which we may from time to time issue and sell American Depositary Shares (“ADSs”) representing our ordinary shares through Cowen in at-the-market (“ATM”) offerings for an aggregate offering price of up to $200 million. As of September 30, 2022, $197,360,000 remained available for sale under the Sales Agreement. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On April 8, 2022 the Company entered into a new sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the nine months ended September 30, 2022, the Company sold 6,681,506 ADSs under the agreement representing 40,089,036 ordinary shares resulting in net proceeds to the Company of $11,413,652 after deducting commissions payable under the 2022 Sales Agreement and estimated issuance costs. As of September 30, 2022, approximately $188,149,700<span style=""white-space:pre-wrap;""> remained available for sale under the 2022 Sales Agreement.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Stockholders' equity,Stockholders' equity,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodValueSalesAgreement_Duration_8_10_2020_To_8_10_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_tn66qs6PaEaIttMcIlLgGg,adap:StockIssuedDuringPeriodValueSalesAgreement,Duration_8_10_2020_To_8_10_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_tn66qs6PaEaIttMcIlLgGg,200000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-6,200000000.0,duration,2020-08-10,2020-08-10,0001621227,http://www.sec.gov/CIK,duration_2020-08-10_2020-08-10,Aggregate offering price of ADS shares under At The Market sales agreement,Aggregate offering price of ADS shares under At The Market sales agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityDetails,None,None,None,None,None,None,None,None,None,srt:MaximumMember,None,None,None,None,adap:SalesAgreementMember,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale_Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_iaTWoD8iAUm3RQ7L7R2n1A,adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale,Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_iaTWoD8iAUm3RQ7L7R2n1A,197360000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,197360000.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Remaining amount under the Sales Agreement (in shares),Remaining amount under the Sales Agreement (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreementMember,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodValueSalesAgreement_Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_Kr8bXTEHIUaltV_mRC64Qg,adap:StockIssuedDuringPeriodValueSalesAgreement,Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_Kr8bXTEHIUaltV_mRC64Qg,200000000,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,-6,200000000.0,duration,2022-04-08,2022-04-08,0001621227,http://www.sec.gov/CIK,duration_2022-04-08_2022-04-08,Aggregate offering price of ADS shares under At The Market sales agreement,Aggregate offering price of ADS shares under At The Market sales agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityDetails,None,None,None,None,None,None,None,None,None,srt:MaximumMember,None,None,None,None,adap:SalesAgreement2022Member,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues_Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,adap:StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues,Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,6681506,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,6681506.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Sold shares represented by American Depositary Shares (in shares),Sold shares represented by American Depositary Shares (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinaryShares_Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,adap:StockSoldDuringPeriodOrdinaryShares,Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,40089036,Unit_Standard_shares_SwwHXl-EiUK2PE8FAWWs5Q,INF,40089036.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Number of ordinary shares sold (in shares),Number of ordinary shares sold (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOrSaleOfEquity_Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,us-gaap:ProceedsFromIssuanceOrSaleOfEquity,Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,11413652,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,11413652.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Net proceeds,Net proceeds,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale_Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale,Duration_1_1_2022_To_9_30_2022_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_msG1KqWVvkajfDahJbDYiA,188149700,Unit_Standard_USD_rpOWAVj1wUCr2U7_xnGB7g,0,188149700.0,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Remaining amount under the Sales Agreement (in shares),Remaining amount under the Sales Agreement (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
us-gaap_SubsequentEventsTextBlock_Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,us-gaap:SubsequentEventsTextBlock,Duration_1_1_2022_To_9_30_2022_uUjGN41zIESxcgsx9yQCvQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 14 – Subsequent events</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""/>On October 25, 2022, the Company announced that GSK will transfer its NY-ESO cell program and the right to the PRAME cell therapy program to Adaptimmune. The terms of the transfer are being negotiated. As part of the transfer, the Company received notice of termination of the Collaboration and License Agreement, effective 60 days following the receipt of notice of termination on October 24, 2022. Once the termination becomes effective, any restrictions applying to Adaptimmune in relation to the collaboration targets (NY-ESO and PRAME) under the Collaboration and License Agreement cease and the licenses Adaptimmune granted to GSK under the Collaboration and License Agreement will cease. Pending completion of the terms for the transfer of the NY-ESO cell therapy program to Adaptimmune, GSK will continue to be responsible for the execution and costs of ongoing clinical trials. The PRAME program is currently preclinical and has not yet been transitioned to GSK. As the terms of the transfer and related agreement are being negotiated, an estimate of the financial effect of this event cannot yet be made.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On November 8, 2022, the Company announced that in order to extend the Company’s cash runway from early 2024 into early 2025, it is re-focusing the business on core programs and deprioritizing non-core programs. It is also undertaking a restructuring of the Company including a headcount reduction of approximately 25% to 30% to be completed in the first quarter of 2023.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2022-01-01,2022-09-30,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-09-30,Subsequent events,Subsequent events,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEvent,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2022-11-08,Q4,2022,Adaptimmune Therapeutics PLC
